Skip to content
Publicly Available Published by De Gruyter August 9, 2022

Psychological management of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review

  • Arthur Sone-Wai Li ORCID logo EMAIL logo , Leesa Van Niekerk ORCID logo , Aquina Lim Yim Wong ORCID logo , Mandy Matthewson ORCID logo and Michael Garry ORCID logo

Abstract

Objectives

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a complex condition. Despite recommendations for the inclusion of non-pharmacological treatment in the management of CP/CPPS, the focus has predominantly been on the inclusion of physical therapies with minimal discussion of psychological interventions. Therefore, this systematic review aimed to evaluate peer-reviewed studies of psychological interventions for men with CP/CPPS to determine their therapeutic efficacy and quality of intervention.

Methods

The review was registered in PROSPERO and based on PRISMA 2020 protocol. The systematic literature search was conducted in six databases. Quantitative studies of psychological intervention for adult men with CP/CPPS that provided outcome measures of pain, quality of life and/or psychological symptoms were reviewed. The Oxford level of evidence and Quality Assessment Tool for Quantitative Studies developed by the Effective Public Health Practice were employed.

Results

A total of 4,503 studies were reviewed; seven met the inclusion criteria. The included studies were randomised controlled trials, cohort, repeated measures, and case-series studies, with most including combined treatment for CP/CPPS. Cognitive therapy, cognitive behavioural therapy, or paradoxical relaxation training were found to be effective. However, high risks of bias were found in all included studies, limiting the generalisability and reliability of findings.

Conclusions

Evidence is preliminary but shows promise for psychological treatment either as a combined or standalone treatment for CP/CPPS. However, there is a need to develop research with a more rigorous methodology to evaluate psychological treatments for men with CP/CPPS.

Introduction

Prostatitis is the third most common urological diagnosis in males [1], and its associated pain symptoms vary across individuals, either with or without pathology (e.g., inflammation or infection) [2]. The National of Institute of Health (NIH) suggests four classifications for prostatitis syndromes; Type III chronic pain/chronic pelvic pain syndrome (CP/CPPS) with non-bacterial aetiology is the most common diagnosis and accounts for approximately 90% of all cases of prostatitis [2, 3]. The prevalence of prostatitis is comparable to other non-communicable diseases such as ischemic heart disease and diabetes mellitus. Evidence from epidemiologic studies indicated that prevalence rates of prostatitis-liked symptoms range from 2.2 to 9.7% internationally [4, 5].

Effective treatment remains challenging for clinicians, and single-modal therapy is generally ineffective [6, 7]. One of the largest barriers to effective treatment is the lack of validated biomarkers (predictors) that can classify patients with the heterogeneous conditions of CP/CPPS into aetiologic or therapeutic categories. The UPOINT phenotyping system was established to inform treatment; this system classifies patients with CP/CPPS and interstitial cystitis into six clinical domains: urinary symptoms [U], psychosocial dysfunction [P], organ-specific symptoms [O], infection [I], neurological/systemic conditions [N] and tenderness of muscles [T] [8]. The psychosocial dysfunction is emphasised by the UPOINT phenotyping system, with 27.6% of CP/CPPS patients experiencing psychosocial problems that required a referral to psychological/psychiatric services [9], and men suffering from CP/CPPS tend to experience various comorbid psychosocial challenges (e.g., depression, anxiety, pain catastrophising cognition, relationship problems, etc.) that significantly interfere with their quality of life (QoL) and daily activities [10, 11]. With the increased recognition of the psychosocial problems associated with CP/CPPS [9], routine psychological intervention is recommended in various international guidelines for chronic pelvic pain [12, 13]. The efficacy of cognitive-behavioural therapy (CBT) [14] and acceptance and commitment therapy (ACT) [15, 16] in chronic pain conditions has been demonstrated in several reviews. Tripp and his colleagues [17] piloted a cognitive-behavioural intervention for men with CP/CPPS, and demonstrated some positive effects in improving pain, catastrophising cognition and QoL but not in depression and some urinary symptoms. Wang and his colleagues [18] have recently conducted a randomised control trial (RCT) examining the efficacy between psychotherapy combined with drug therapy and drug-alone therapy in the management of CP/CPPS. The authors found that whilst drug-alone therapy only improved prostatitis-liked symptoms, the combined therapy showed marked improvement in all symptoms including depression, anxiety and sexual dysfunction [18].

While increasing research has been conducted in examining the role of pharmacological treatment [6, 19] and physiotherapy [20] for CP/CPPS, the role of psychotherapy is unclear. Moreover, a recent Cochrane review [21] that examined the effects of non-pharmacological interventions for CP/CPPS has found some effects of alternative approaches (e.g., acupuncture, extracorporeal shockwave therapy), physical activity and lifestyle modification in reducing symptoms of CP/CPPS. However, this review reported no information regarding psychological interventions [21]. This study aims to systematically summarise and synthesise the available evidence for psychological interventions for men with CP/CPPS. Additionally, we aim to examine which treatment modalities are used in the psychological management of CP/CPPS as well as their efficacy.

Methods

Database sources and searches

The review was registered in the International Prospective Register of Systematic Review (PROSPERO; CRD4201912746). The design, conduct and reporting of studies were based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020) [22] statement. Six databases were searched. Medline and Embase were searched because they are the most comprehensive sources of reported control trials [23]. Web of Science, Scopus, PsycINFO and CINAHL were also searched because they are subject-specific databases that provide valuable information about various psychological interventions. Each phrase of the search strategy was searched in the categories “title” and “abstract” and, where possible, in the controlled vocabulary or thesaurus (e.g., MeSH, Emtree, CINHAL headings, and PsychINFO thesaurus) of the particular database. Adaptations of the search strategy were made for databases that do not have subject headings and/or limitations in the composition of search terms. Hand searching was also performed on reference lists of full-text articles in order to capture publications that may be overlooked in the online search.

To detect as many relevant studies as possible, the search terms focused on a set of words that are: (1) synonyms for the pain condition, (2) synonyms for the psychotherapy, (3) synonyms for the treatment modality and (4) synonyms for multimodal or non-pharmacological treatment. As the phrase “persistent pelvic pain” only captures studies with female participants, which was not included in the search terms. Synonyms for each group were connected using the Boolean operator OR and the groups between pain conditions and treatment-related terms were connected with AND. The full search strategy is provided in the Supplementary Appendix.

Study selection

Inclusion criteria were developed to capture all relevant studies regarding psychotherapy for CP/CPPS, and these were based on five domains: (a) study type – any primary research with quantitative study type, e.g., retrospective or prospective studies; (b) population – males who were over 18 years of age and were claimed to have CP/CPPS or prostatitis-liked symptoms by the study authors; (c) intervention – modalities of psychotherapy were specified as either active or passive treatment and delivery as either individual- or group-based treatment; (d) outcome – pain reduction, improvement in the QoL and/or improvement in psychological symptoms as primary outcome parameters; and (e) publication – studies written in English or Chinese; studies written in other languages were excluded. Studies were only eligible if they were original work published in peer-reviewed journals; other types of publication such as congress-presentation or posters were excluded.

Screening and data collection

Two independent researchers (AL, LVN) scanned titles and abstracts of yielded articles for inclusion in the present review. The full texts of eligible studies were retrieved for further screening. A third researcher (AW) were involved in the screening process for studies written in Chinese. To minimise errors and subjective judgements, researchers conducted the screening independently. Where consensus among the first three researchers cannot be reached, a fourth researcher (MM) made the final determination. Any inconsistencies were resolved by discussion.

Assessment of quality of studies and risk of bias

Studies were ranked in hierarchical order according to the study type using the Oxford Levels of Evidence created by OCEBM Levels of Evidence Working Group [24]. A study with a higher ranking (from level 1 to 4) has more methodological strengths in its study design than those with a lower ranking [25]. Assessments of study quality were performed using the Quality Assessment Tool for Quantitative Studies developed by Effective Public Health Practice Project (EPHPP) [26, 27]. This tool assesses eight domains of risk of bias, including (A) selection bias, (B) allocation bias, (C) confounders, (D) blinding, (E) data collection methods, (F) withdrawals and dropouts, (G) intervention integrity, and (H) analysis. Each domain can be rated using the criteria of “strong”, “moderate” and “weak” to indicate quality and “low”, “moderate” and “high” to indicate risk of bias. For the determination of overall study quality, a study was assessed as “strong” if no weak ratings from (A) to (F) were obtained, “moderate” if one weak rating was obtained and “weak” when two or more weak ratings were obtained.

The first two researchers (AL, LVN) assessed the risk of bias and study quality using the assessment tool, and the third researcher (AW) involved in the assessment for studies written in Chinese. The full consensus was reached among the first three authors.

Data synthesis and analysis

Narrative data synthesis was conducted using Guidance on the Conduct of Narrative Synthesis in Systematic Reviews [28]. This type of analysis was conducted given the heterogeneous nature of the studies included in the review.

Results

Search results

The Covidence software was employed in the process of screening and articles identification. The initial search returned 4,503 potential studies. After the removal of duplicates, 3,518 studies were screened by title and abstract. 3,475 studies were excluded according to the selection criteria, resulting in 43 studies being eligible for full-text screening with 100% inter-rater agreement. Of the 43 eligible studies, only 40 of them were able to retrieve the full-text articles. After assessing the full-text articles, 34 studies were further excluded because of: study type (e.g., treatment protocol, phenotype directed therapy, 14 studies), population (e.g., female patients or missing information of pain condition or patients’ characteristics, three studies), intervention (e.g., no psychological interventions used, four studies), publication (e.g., written in Russian and German, conference paper, six studies), and others (e.g., duplicates, same population, six studies). An additional study was identified by citation searching. In total, seven studies met the selection criteria and were included in the narrative review. The search was extended through November 2021 to ensure relevant studies were included at the time of publication, and no additional studies were identified. The PRISMA 2020 flow diagram is shown in Figure 1 that summarises the screening process and final search results.

Figure 1: 
            PRISMA 2020 flowchart illustrating search and screening process of the systematic review.
Figure 1:

PRISMA 2020 flowchart illustrating search and screening process of the systematic review.

Overview of study characteristics

The seven studies included research from America, Canada and China, published from 2006 to 2018. Six studies included male participants with a diagnosis of either NIH Type IIIa/IIIb prostatitis, and one study recruited male and female participants with urological chronic pelvic pain syndrome (UCPPS) diagnosis. These studies were heterogeneous in terms of design, intervention evaluated, and outcome measurements. The information of characteristics for each study (including country, population, study type, number of participants, age, symptom duration and setting/context) is shown in Table 1.

Table 1:

Characteristics of included studies: country, population, study type, number, age, symptom duration and setting/context.

Study (Country) Population Study type Intervention group Control group Recruitment/Context/Consent Dropouts/Withdrawals
Number, age and symptom duration Number, age and symptom duration
Anderson et al. (US) [29] Men with NIH-III CPPS diagnosis Case series study (retrospective) 146 men, mean age 42 (range 18–77), mean 74 months (3–447) n/a Referral to urology clinic at Stanford University Hospital. No information about consent Not reported. 146 men received treatments for at least 1 month or longer
Anderson et al. (US) [30] Men with either NIH IIIA/IIIB prostatitis or specific location of pelvic pain Case series study (prospective) 200 men, median age 48 (range 19–80; IQR 36, 54), median 4.8 years (range less than 1–30) n/a Self-referral to the 6 days protocol, at urology clinic, Stanford University Hospital. No information about consent Not reported. A total of 200 men entered the protocol through the Stanford clinic and 116 provided follow-up questionnaires
Anderson et al. (US) [31] Men and women with urological chronic pelvic pain syndrome (UCPPS) diagnosis Cohort study (prospective) 314 men, median age 41, median 60 months 79 women, median age 49, median 60 months Self-referral to the 6 days protocol, at urology clinic, Stanford University Hospital. All patients signed an informed consent form before enrolment Not reported. There were 393 patients met study inclusion criteria. 313 men and 79 women
Lu & Jiang (China) [32] Men with CP following sexually transmitted diseases (STD) RCT 42 men, mean age 33.29 (SD=8.35), mean 16.52 months (SD=6.22) 42 men, mean age 32.38 (SD=7.62), mean 15.33 months (SD=7.37) Recruited from department of dermatology, Guangzhou eighth People’s Hospital. No information about consent Not reported. Intervention (n=42) and control groups (n=42) completed treatment for 1 month
Tripp et al. (Canada) [17] Men with a CP/CPPS diagnosis Repeated measures study 11 men, mean age 51.3 (SD=12.49, range 29–66), mean 5.42 years (SD=3.06) Recruited from Urology Prostatitis Clinic (JCN). 13 subjects were eligible and 11 consented to participate 11 patients enrolled in and completed the program. Compliance with the protocol was excellent; the only missing data was upon termination in three of the 11 in completing the CPSI follow-up. Of these three men, two did not complete the full set of questions making their CPSI data void, while the third man could not be contacted
Wang et al. (China) [18] Men with NIH-III CP/CPPS diagnosis RCT 78 men, mean age 37.5 (SD=8.3), mean 3.4 years (SD=2.1) 78 men, mean age 36.4 (SD=8.1), mean 3.2 years (SD=2.0) Recruited from Binzhou Medical University Hospital. Written informed consent was obtained from all participants Among 165 patients who met the inclusion criteria, seven patients were voluntarily discharged from the study and two patients were not involved for other reasons, therefore just 156 patients finally completed the study
Zhuang et al. (China) [33] Men with NIH-IIIA prostatitis RCT 87 men, mean age 34.7 (SD=4.1), mean 20.1 months (SD=8.9) 80 men, mean age 34.7 (SD=4.1), mean 20.1 months (SD=8.9) Recruited from general Hospital of Guangzhou military command of PLA. No information about consent Not reported. Intervention (n=87) and control groups (n=80) completed treatment for 8 weeks
  1. CP, Chronic Prostatitis; CPPS, Chronic Pelvic Pain Syndrome; NIH, National Institutes of Health; RCT, Randomised Control Trial.

Three modalities of psychological intervention were implemented in these included studies. Two studies [17, 18] included group-based CBT with key strategies including identifying and modifying unhelpful thoughts/behaviours, relaxation techniques, and coping skills training. Two studies [32, 33] included cognitive therapy (CT) that focuses on identifying and changing irrational/anxiety-provoking thoughts. Three studies [29], [30], [31] included paradoxical relaxation training delivered by (clinical) psychologists that aims to modify the habitual tendency to tighten pelvic floor muscle and to reduce anxiety. Of the seven included studies, six studies reported treatment regime combining psychological intervention with physiotherapy and/or drug treatment, e.g., myofascial trigger point release with paradoxical relaxation training, CT with drug-alone treatment and CBT with drug-alone treatment. One study pilot-tested psychological intervention – CBT as an active treatment in the management of CP/CPPS. The detailed information of psychological intervention is shown in Table 2.

Table 2:

Characteristics of included studies: description of intervention, components of psychological intervention.

Study (Country) Description of intervention group Description of control group
Anderson et al. (US) [29] (91 men with) n/a
Myofascial trigger point release: Weekly for 4 weeks & biweekly for 8 weeks thereafter; and

Paradoxical relaxation training & specific breathing technique for anxiety: Weekly and biweekly intervals for eight sessions; and

Daily home practice relaxation sessions of 1 h, for a minimum of 6 months
Case series study (retrospective) (55 men with)
Modified 6-day intensive protocol, 30-h intensive treatment that involved myofascial trigger point release and Paradoxical relaxation training
Anderson et al. (US) [30] 6-day intensive treatment protocol that included: n/a
Case series study (prospective) Myofascial trigger point release: 30–60-min sessions each day; and

Paradoxical relaxation training: A psychologist provided daily instruction, 3–5 h per day. Focusing on reducing nervous system arousal in the presence of catastrophic thinking and perceived pain; and

Self-treatment: A 2-year program of recorded relaxation instruction & being instructed how to stretch and enhance relief of muscle tension
Anderson et al. (US) [31] (Men) (Women)
6-day intensive treatment protocol that included 6-day intensive treatment protocol that included
Cohort study (prospective) Myofascial trigger point release: Five consecutive days; and Paradoxical relaxation training: A clinical psychologist provided daily instruction. Focusing on reducing nervous system arousal in the presence of catastrophic thinking and perceived pain in pelvic floor muscle; and

Self-treatment: Trigger point release using internal myofascial trigger point wand, 2–4 times per week & extensive set of audio recordings as a guide for home practice of paradoxical relaxation training
Myofascial trigger point release: Five consecutive days; and Paradoxical relaxation training: A clinical psychologist provided daily instruction. Focusing on reducing nervous system arousal in the presence of catastrophic thinking and perceived pain in pelvic floor muscle; and Self-treatment: Trigger point release using internal myofascial trigger point wand, 2–4 times per week & extensive set of audio recordings as a guide for home practice of paradoxical relaxation training
Lu & Jiang (China) [32] Cognitive Therapy (CT): For 1 month. Treatment component included identifying and modifying irrational thoughts that lead to anxiety, counselling; and

Drug treatment: Levofloxacin, tamsulosin
Drug treatment: Levofloxacin, tamsulosin
RCT
Tripp et al. (Canada) [17] Cognitive Behavioural Therapy (CBT): Delivered by nurses and equivalent health care provider, group based, weekly eight session, 1 h per session. Treatment component included education about cognitive and behavioural approach (1st session), identifying and modifying catastrophic cognitions (2nd & 3rd sessions), positive communication practice (4th & 5th sessions), modifying illness-focused behaviours and re-engaging social/physical activities (6th & 7th sessions) and problem-solving and risk factor modification (8th session); and n/a
Repeated measures study
Wang et al. (China) [18] Cognitive Behavioural Therapy (CBT): Delivered by a consultant clinical psychologist, group based, two 2 h session held weekly, for 12 weeks. Treatment component included health education, identifying and modifying unhelpful thoughts or behaviours, relaxation techniques and stress management, coping skills training and application, family and social support, group discussion regarding sleep, relaxation, stress and behavioural changes; and

Drug treatment: Levofloxacin, tamsulosin
Drug treatment: Levofloxacin, tamsulosin
RCT
Zhuang et al. (China) [33] Cognitive Therapy (CT): For 8 weeks, individual based. Treatment component included health education, identifying and modifying anxiety-provoking thoughts, encouraging normal sexual life and physical activity and psychological support; and Drug treatment: Levofloxacin, tamsulosin Drug treatment: Levofloxacin, tamsulosin
RCT
  1. Text in bold indicates the psychological intervention implemented in the study.

Regarding the measurements, there was substantial variability in outcomes and domains measured across the seven studies. All studies employed the National of Institute of Health – Chronic Prostatitis Symptom Index (NIH-CPSI) to assess treatment outcomes, except for one study [31] using a 10-points Likert scale. All studies reported primary outcomes of interests of pain level and urinary symptoms. However, the psychosocial outcomes were only reported in six out of seven studies; these outcomes are QoL impact, anxiety, depression/depressive symptoms, pain catastrophising cognition, sexual function, erectile dysfunction and perceived social support. The outcomes and domains measured in each study can be seen in Table 3 and Figure 2.

Table 3:

Results of studies.

Study (Country) Measures: pain/urinary symptoms outcomes Measures: psychosocial outcomes
Anderson et al. (US) [29] NIH-CPSI Pelvic Pain Symptom Survey (PPSS) Pelvic Pain Symptom Survey (PPSS)
Case series study (retrospective) Total symptoms | markedly group defined by score decreased by 70%=mean difference=−9.2 (p<0.001); moderately group defined by score decreased by 50% or greater=mean difference=−7.0 (p<0.001) Pain | markedly group defined by score decreased by 70%=mean difference=−6.5 (p<0.001); moderately group defined by score decreased by 50% or greater=mean difference=−4.4 (p<0.001) Sexual Function | markedly group defined by score decreased by 70%=mean difference=−3.3 (p<0.001); moderately group defined by score decreased by 50% or greater=mean difference=−1.1 (p=0.96)
Pain | markedly group defined by score decreased by 70%=mean difference=−4.7 (p<0.001); moderately group defined by score decreased by 50% or greater=mean difference=5.0 (p<0.001) Urinary | markedly group defined by score decreased by 70%=mean difference=−3.6 (p<0.001); moderately group defined by score decreased by 50% or greater=mean difference=−4.0 (p<0.001)
Anderson et al. (US) [30] NIH-CPSI Pelvic Pain Symptom Survey (PPSS) NIH-CPSI 5-point Likert scale
Total Symptom | median difference=−7 (p<0.001) Pain | median difference=−4 (p<0.001) QoL Impact | median difference=−3 (p<0.001) Psychological Status | median difference=−14 (p<0.001)
Case series study (prospective) Pain | median difference=−3 (p<0.001) Urinary Symptoms | median difference=−4.5 (p<0.001) Pelvic Pain Symptom Survey (PPSS)
Urinary Symptoms | median difference=−2 (p<0.001) Pain Visual Analog Scale (VAS) a Sexual Function | median difference=−2 (p<0.001)
Pain | median difference=−1 (p<0.001)
Anderson et al. (US) [31] 10 point scale a 10-point scale a
Cohort study (prospective) Total Symptom | median difference=2.5 (in men) Emotional Distress | median difference=−2 (in men)
Lu & Jiang (China) [32] NIH-CPSI
RCT Total Symptom | markedly group defined by score decreased by 90%=14 patients (33.3%); effective group defined by score decreased by 60–89%=21 patients (50%); No effect group defined by score decreased less than 59%=seven patients (16.67%); between group difference=X2=3.94 (p<0.05)
Tripp et al. (Canada) [17] NIH-CPSI Short-Form McGill Pain Questionnaire (SF-MPQ) Center for Epidemiological Studies Depression Scale (C-ESD) The Multidimensional Scale of Perceived Social Support (MSPPS)
Total Symptom | pre-post mean difference=−7.25 (p=0.007); between group difference= Depression Symptoms | across eight sessions=F=0.776 (p=0.399) Perceived Social Support | across eight sessions=F=0.438 (p=0.532)
Repeated measures study Pain | pre-post mean difference=−3.38 (p=0.015) Pain | | across eight sessions=F=4.875 (p=0.49) Pain Catastrophizing Scale (PCS) Pain Disability Index (PDI)
Urinary Symptoms | pre-post mean difference=−0.87 (p=0.087) Pain catastrophizing cognition | across eight sessions=F=12.896 (p=0.005) Disability | across eight sessions=F=7.702 (p=0.20)
NIH-CPSI
QoL Impact | pre-post mean difference=−3 (p=0.013)
Wang et al. (China) [18] NIH-CPSI Self-Rating Anxiety Scale (SAS) International Index of Erectile Function (IIEF-5)
Anxiety | pre-post mean difference=−8.8 (p<0.001); between group difference (p<0.001)
RCT Total Symptom | pre-post mean difference=−14.1 (p<0.001); between group difference (p<0.001) Self-Rating Depression Scale (SDS) Erectile Function | pre-post mean difference=7.1 (p<0.001); between group difference=(p<0.001)
Depression | pre-post mean difference=−6.4 (p<0.001); between group difference=(p<0.001)
Zhuang et al. (China) [33] NIH-CPSI Self-Rating Anxiety Scale (SAS) International Index of Erectile Function (IIEF-5)
Anxiety | pre-post mean difference=−16 (p<0.01); between group difference=(p<0.01)
RCT Total Symptom | pre-post mean difference=−14 (p<0.01); between group difference=(p<0.01) Self-Rating Depression Scale (SDS) Erectile Function | pre-post mean difference=8.1 (p<0.01); between group difference=(p<0.01)
Depression | pre-post mean difference=−12.4 (p<0.01); between group difference=(p<0.01)
  1. RCT, Randomised Control Trial; NIH-CPSI, The National Institutes of Health Chronic Prostatitis Symptom Index; QoL, Quality of Life. Text in bold indicates the psychological intervention implemented in the study. astatistical significance was not reported.

Figure 2: 
            Variability in outcomes and domains measured in included studies. NIH-CPSI, The National Institutes of Health Chronic Prostatitis Symptom Index.
Figure 2:

Variability in outcomes and domains measured in included studies. NIH-CPSI, The National Institutes of Health Chronic Prostatitis Symptom Index.

Assessment of quality of studies and risk of bias

The study types included case-series studies (retrospective and prospective), cohort study (prospective), repeated measures study and RCTs. All studies examined the effects of pre-post treatment, and only four studied included randomisation and control groups (but not placebo groups) for comparison with the treatment of interest.

Following the Oxford Level of Evidence [24], three of the seven included studies were RCTs [18, 32, 33] and were ranked as evidence level 2. The cohort [31] and repeated measures studies [17] were ranked as evidence level 3. The remaining two studies were case-series studies [29, 30], with a ranking of evidence level 4.

Figure 3 provide a summary of the risk of bias and quality assessment for all studies. All studies received at least three ratings of “weak” quality or “high” risk of bias using the EPHPP criteria. Confounders bias and the lack of Blinding are main areas of concern. All studies were rated as “weak” or “high” in these two criteria, indicating that all included studies did not conduct adequate measures to manage these procedures.

Figure 3: 
            Risk of bias and study quality assessment for the eight criteria. Colour green indicated “low” risk of bias and “strong” quality and; Colour yellow indicated “moderate” risk of bias and “moderate” quality; Colour red indicated “high” risk of bias and “low” quality and, colour red. Overall ratings of study quality: study was assessed as “strong” if no weak ratings from (A) to (F) were obtained, “moderate” if one weak rating was obtained and “weak” when two or more weak ratings were obtained.
Figure 3:

Risk of bias and study quality assessment for the eight criteria. Colour green indicated “low” risk of bias and “strong” quality and; Colour yellow indicated “moderate” risk of bias and “moderate” quality; Colour red indicated “high” risk of bias and “low” quality and, colour red. Overall ratings of study quality: study was assessed as “strong” if no weak ratings from (A) to (F) were obtained, “moderate” if one weak rating was obtained and “weak” when two or more weak ratings were obtained.

Study results

The seven studies were grouped according to the modality of psychotherapy implemented as intervention, and the following paragraphs summarise the study results of the different interventions. The results of each study are shown in Table 3.

Cognitive behavioural therapy

The samples of the two studies evaluating CBT ranged from 11 [17] to 156 [18] participants, with a mean age between 37.5 [18] and 51.3 [17] years. Both studies included male participants recruited from single medical sites and diagnosed with CP/CPPS. One study was a RCT [18] comparing combined CBT and drug treatment with drug-alone treatment. The other one [17] was a pilot test examining the effect of CBT before and after treatment. These studies employed group-based CBT; one was delivered by a nurse or equivalent healthcare worker [17], and the other was by a clinical psychologist [18]. Despite some differences in treatment components, both psychological interventions included key cognitive-behavioural strategies such as identifying and modifying unhelpful/catastrophic cognitions, training behavioural coping skills and modifying maladaptive behaviours. The treatment intensity differed in these studies; the RCT [18] implemented intervention for 12 weeks with two 2-h sessions held weekly, whereas the pilot test study [17] held 1-h session weekly for 8 weeks. The NIH-CPSI was used as a measurement of CP/CPPS symptoms in both studies. However, the measurements and outcomes of interest for psychosocial outcomes differed between studies, although both included measures of depression. The RCT [18] showed that CBT combined with drug treatment may have reduced CP/CPPS symptoms measured by NIH-CPSI (pre-post mean difference [MD]=−14.1, p<0.001), and its effect was significantly stronger than drug-alone treatment (p < 0.001). Significant improvements were also reported in measures for depression (pre-post MD=−6.4, p<0.001), anxiety (pre-post MD=−6.4, p<0.001) and erectile function (pre-post MD=7.1, p<0.001). The pilot test study [17] examining CBT efficacy indicated significant deduction in CP/CPPS symptoms, measured by NIH-CPSI (pre-post MD=−7.25, p=0.007). These lower scores were observed across the subscores of pain and QoL impact, except for urinary symptoms. The same study also reported significant changes in validated measures, across eight intervention sessions, for catastrophising cognition (F=12.87, p=0.005) and pain disability (F=7.70, p=0.020), but not for depression and perceived social support.

Cognitive therapy

Two RCTs compared the combined CT and drug treatment with drug-alone treatment, with male samples ranging from 84 (mean age of 33.29) [32] to 167 (mean age of 34.7) [33]. One study [32] implemented CT for 4 weeks, whereas the other [33] for 8 weeks. The CT was delivered individually to patients, with a key treatment component of identifying and modifying irrational/anxiety-provoking cognitions. Both RCTs employed NIH-CPSI in assessing the treatment outcome of CP/CPPS symptoms. However, only the latest RCT [33] included measures of psychosocial outcomes, including depression, anxiety and erectile function.

The latest study [33] indicated that combined CT and drug treatment may have reduced CP/CPPS symptoms measured by NIH-CPSI (pre-post MD=−14, p<0.01) and was more effective than drug-alone treatment (p<0.01). Significant improvements were also reported in measures for depression (pre-post MD=−12.4, p<0.01), anxiety (pre-post MD=−16, p<0.01) and erectile function (pre-post MD=8.1, p<0.01). The older RCT [32] reported data in subgroups according to patients’ responsiveness to treatment; they found that 83.3% of CP/CPPS patients, who received combined CT and drug treatment, achieved more than 60% reduction in NIH-CPPS total symptoms score pre-post treatment.

Paradoxical relaxation training

Two case-series studies and one cohort study examined the effect of combining myofascial trigger point therapy and paradoxical relaxation training on CP/CPPS. The male samples of the two case-series studies ranged from 146 (mean age=42) [29] to 200 (median age=48) [30]. All participants in case-series studies have a diagnosis of NIH-III CP/CPPS. The cohort study recruited male (n=314) and female (n=74) patients with a diagnosis of urological chronic pelvic pain syndrome (UCPPS). The paradoxical relaxation training in these studies was delivered by a (clinical) psychologist and focused on reducing nervous system arousal in the presence of catastrophic thinking and perceived pain. Two case-series studies used the NIH-CPSI as outcome measures for pain and urinary symptoms, whereas the cohort study used the NIH-CPSI for baseline measure but a 10-Likert scale for outcome measure of CP/CPPS symptoms. The Pelvic Pain Symptoms Survey (PPSS) was also employed in both case-series studies in assessing pain, urinary symptoms and sexual function outcomes. Only the latest case-series study [30] and the cohort study [31] measured the outcomes of psychological/emotional distress after treatment, but with different measurements. The latest case-series study [30] reported statistically significant changes in outcomes of NIH-CPSI total symptom (median difference=−7, p<0.001), pain (median difference=−3, p<0.001), urinary symptoms (median difference=−2, p<0.001). The study also reported significant improvement in psychosocial outcomes: QoL impacts (median difference=−7, p<0.001), sexual dysfunction (median difference=−2, p<0.001), and psychological status (median difference=−14, p<0.001). The older one [29] presented data in subgroups according to patients’ responsiveness to treatment; the study reported significant changes in pain, urinary symptoms and sexual dysfunction in subgroups of markedly and moderately improved patients. The cohort study [31] also demonstrated similar results in the male cohort, indicating significant improvements in CP/CPPS symptoms and emotional distress.

Discussion

Evidence of psychological interventions

This systematic review synthesised the available evidence regarding psychological intervention for men with CP/CPPS and their efficacy. A total of seven studies were examined according to the Oxford Level of Evidence [24] – three studies were RCT with a higher ranking of evidence level 2; two studies were the cohort and repeated measures studies and were ranked as evidence level 3; the remaining two studies were case-series studies with evidence level 4. Evidence from all levels demonstrated the potential benefit of integrating psychological interventions in the treatment of CP/CPPS in improving pain, total symptoms and psychological outcomes. Also, preliminary evidence suggests using psychological interaction as an active treatment for CP/CPPS, with significant outcomes on pain reduction and improvements in some aspects of psychosocial symptoms.

A reduction by six points or more in NIH-CPSI total symptoms score has been considered a clinically meaningful change in CP/CPPS condition [34]. The findings in this review indicated that psychological interventions combined with drug treatment produced clinically meaningful outcomes for CP/CPPS (MD in NIH-CPSI total score −7.25 to −14). The effect is comparable to other non-pharmacological approaches and even outweighs the drug-alone treatment [19, 21] Moreover, the findings indicated that combining psychological interventions with drug treatment improves psychosocial outcomes.

Cognitive behavioural therapy

There is some evidence for the beneficial effect of CBT [17, 18]. The RCT compared the effects of combined CBT and drug therapy with a drug-alone regime. While both regimes showed meaningful improvements in total symptoms and erectile dysfunction pre-post treatment, only the combined regime showed significant improvements in psychological symptoms: depression and anxiety. However, the authors reported no blinding procedure in their study, and the risk of allocation bias may have influenced the results. Also, the study did not include a placebo group for comparison; therefore, the efficacy of a combined regime (or drug-alone regime) is unclear compared to groups with no active treatment. Moreover, the intensity level of the CBT program was relatively high – two 2-h sessions per week, for 12 weeks. It is unclear if the treatment effect of CBT on psychological outcomes was attributed to the high intensity of treatment [18]. In the repeated measures study, CBT significantly improved pain outcomes, the impact of QoL, pain catastrophising and disability, but it failed to produce meaningful effects on urinary symptoms, depressive symptoms and perceived social support. Nevertheless, this study was a pilot test with a small cohort and no control group for comparison. The authors also reported a risk of selection bias. Therefore, the generalisability of the findings is limited.

Cognitive therapy

Some evidence for CT is gained from two RCTs [32, 33]. These RCTs compared the combined CT and drug therapy with standard drug-alone therapy. They found that the combined regime outperformed the drug-alone therapy in total symptoms measured by NIH-CPSI. However, these RCTs only included active treatment groups but no placebo group for comparison. Also, no validated measures were employed to assess psychosocial symptoms, and the symptom severity was unknown. Moreover, patients in these RCTs were from one hospital site, which may lead to a potential risk of selection bias and limit the generalisability of the findings.

Paradoxical relaxation training

Two case-series studies [29, 30] showed some effects of integrating paradoxical relaxation training with trigger point therapy in managing CP/CPPS. These studies found meaningful improvements in total symptoms, pain and urinary symptoms as measured by NIH-CPSI. The latest case-series study [30] also found meaningful improvements in psychological status. In addition to evidence from case series studies, one cohort study [31] reported similar results of the combined treatment in improving total symptom and emotional distress. Nonetheless, these studies have various methodological limitations.

The absence of control groups and randomisation and blinding procedures in case-series and cohort studies may have limited the generalisability of the results. Also, patients in these studies were recruited from one hospital site, which left a potential risk of selection bias. Moreover, the treatment duration among these studies was inconsistent. For instance, the older case-series study [29] had a treatment duration of approximately 8 weeks, whereas the latest case-series study [30] and the cohort study [31] were for 6 days. The mixed treatment procedures reported in the older case-series study may also intricate the findings. For example, 55 of 146 men received 6-day intensive treatment, whereas the rest received treatment for approximately 8 weeks [29].

The analysis of outcome measures also varied in these studies. The case-series studies used the global response assessment to classify treatment outcomes; rather than presenting the raw data, the authors grouped patients into two categories – markedly and moderately group – based on the degree of pain improvement. Scores were also reported differently across studies, either in mean or median. With the variation in analysis, it remains unclear about the total efficacy of the treatment because no grand mean scores were reported.

Limitations to the evidence: gaps in the literature

Despite some evidence for the utility of psychological components for CP/CPPS, the evidence is subject to a high risk of bias. One striking result was that the overall study quality for all included studies was rated as “weak”. All studies were subject to a high risk of confounding bias; they did not implement adequate measures to control for the possible confounding effects. Most studies considered the combined treatment as one unit for the management of CP/CPPS and did not measure the individual effect of each treatment component. Therefore, the results could not show how much treatment outcomes are accounted for by psychological components. Moreover, most studies did not systematically examine or control for the possible confounders, for instance, engagement in sedentary job [35], alcohol consumption [35], and history of anxiety, depressive and trauma-related disorder [36, 37]. Furthermore, all included studies did not implement the blinding procedure that may inflate the risk of performance bias – participants in the experimental group receive more clinical attention from researchers/practitioners than the other groups. Selection and allocation biases also existed in most studies, which further limit the generalisability of the evidence.

In addition to methodological issues, some practical issues may limit the reliability of the evidence. While we extensively searched for the literature on psychosocial interventions for CP/CPPS, only seven studies were found. Due to the small number, conducting a meta-analysis was impossible. Consequently, clear estimates of effect size for different types of psychosocial interventions are not available. Also, most included studies did not use validated measure for (or did not measure) psychosocial outcomes. It is difficult to conclude how psychological intervention improves the psychosocial symptoms in patients with CP/CPPS.

Recommendations for psychological interventions for CP/CPPS

CP/CPPS is a complex condition that requires a management plan beyond the biomedical approach. Updated treatment guidelines [12, 13, 38] recommend psychological interventions as part of the treatment component for CP/CPPS. The findings of this review provide some evidence of the additive effects of psychological interventions on reducing psychological symptoms when compared with monotherapy. This supports taking a biopsychosocial or multimodal approach for managing CP/CPPS.

As biopsychosocial conceptualisation of CP/CPPS is important, it is recommended that practitioners conduct a comprehensive assessment to identify therapeutic goals. Research has shown the mediating role of pain catastrophising on the relationship between pain and physical and mental QoL [39], and a reduction in pain catastrophising is associated with improved pain outcome and QoL [40, 41]. Other potential mediators of treatment include depression and anxiety [42], [43], [44]. We recommend practitioners routinely assess for catastrophising thoughts, depression and anxiety using psychometrically sound measures with established clinical cut-offs. These measures include, but are not limited to, Pain Catastrophising Scale (PCS) [45], Depression Anxiety Stress Scales – 21 items version (DASS-21) [46], Patient Health Questionnaire Depression Scale (PHQ-9) [47], or Generalized Anxiety Disorder – 7 items (GAD-7) [48]. A referral to psychological or psychiatric services is recommended if patients with CP/CPPS indicate a clinical or moderate level in these measures.

Recommendations for further research

Further research into psychosocial interventions for CP/CPPS should use a more rigorous methodology and carefully select outcome measures congruent with research questions and the intervention type. NIH-CPSI is widely used to assess pain, urinary symptoms and impact of QoL. However, this measurement is limited in its ability to characterise the complexity of CP/CPPS, especially the psychosocial components. Researchers are recommended to incorporate recommendations from The Initiative on Methods, Measurements and Pain Assessment in Clinical Trials (IMMPACT) [49, 50] when selecting outcome measures suitable for pain clinical trials. New research on psychosocial interventions for CP/CPPS should include psychometrically sound measures of psychosocial symptoms and experiences of CP/CPPS and pain cognitions.

Since CT and CBT appear to be promising, it is crucial to test these approaches in a rigorous study design, including a large sample size to minimise the potential biases. This will undoubtedly build upon the work that has been conducted in this area to date. Future research should also examine the effects of other psychological intervention programs such as Acceptance and Commitment Therapy. Moreover, it is recommended that future research involves the development of a treatment protocol including CBT and other evidence-based interventions and examine its treatment effects on important psychosocial mechanics in CP/CPPS.

Conclusions

All studies included in this review suggest that psychological interventions for men with CP/CPPS will likely be beneficial for this population. Nonetheless, this field is in its infancy, and practitioners/researchers have the opportunity to make a significant contribution to the way that men with CP/CPPS are treated. This can be achieved by conducting intervention studies with methodologically rigorous design, using validated measures to assess relevant biopsychosocial factors, and identifying important treatment targets. As such, a clearer picture of the effects of psychotherapy can be obtained which help to inform better treatment plan and can optimise the treatment outcomes for men with CP/CPPS.


Corresponding author: Arthur Sone-Wai Li, MPsych(Clin), School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Churchill Ave, 7005, Hobart, TAS, Australia, Phone: +61 3 6226 2241, Fax: +61 3 6226 2883, E-mail:

  1. Research funding: We have no support or funding for the reporting.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission

  3. Competing interests: We declare that no competing interests exist.

References

1. Collins, MM, Stafford, RS, O’Leary, MP, Barry, MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224–8. https://doi.org/10.1016/S0022-5347(01)63564-X.Search in Google Scholar

2. Krieger, JN, Nyberg, L Jr, Nickel, JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236–7. https://doi.org/10.1001/jama.282.3.236.Search in Google Scholar PubMed

3. Almugbel, SK, Alanezi, FKB, Alhoshan, FM, Alkhalifa, RO, Alkhzaim, AH, Almohideb, MA. Classification and treatment of prostatitis: a review of literature. Int J Community Med Public Health 2018;5:4941–6. https://doi.org/10.18203/2394-6040.ijcmph20184247.Search in Google Scholar

4. Liang, CZ, Li, HJ, Wang, ZP, Xing, JP, Hu, WL, Zhang, TF, et al.. The prevalence of prostatitis-like symptoms in China. J Urol 2009;182:558–63. https://doi.org/10.1016/j.juro.2009.04.011.Search in Google Scholar PubMed

5. Krieger, JN, Lee, SW, Jeon, J, Cheah, PY, Liong, ML, Riley, DE. Epidemiology of prostatitis. Int J Antimicrob Agents 2008;31(1 Suppl):S85–90. https://doi.org/10.1016/j.ijantimicag.2007.08.028.Search in Google Scholar PubMed PubMed Central

6. Cohen, JM, Fagin, AP, Hariton, E, Niska, JR, Pierce, MW, Kuriyama, A, et al.. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One 2012;7:e41941. https://doi.org/10.1371/journal.pone.0041941.Search in Google Scholar PubMed PubMed Central

7. Zhao, Z, Zhang, J, He, J, Zeng, G. Clinical utility of the UPOINT phenotype system in Chinese males with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a prospective study. PLoS One 2013;8:e52044. https://doi.org/10.1371/journal.pone.0052044.Search in Google Scholar PubMed PubMed Central

8. Shoskes, DA, Nickel, JC, Rackley, RR, Pontari, MA. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009;12:177–83. https://doi.org/10.1038/pcan.2008.42.Search in Google Scholar PubMed

9. Doiron, RC, Tripp, DA, Tolls, V, Nickel, JC. The evolving clinical picture of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a look at 1310 patients over 16 years. Can Urol Assoc J 2018;12:196–202. https://doi.org/10.5489/cuaj.4876.Search in Google Scholar PubMed PubMed Central

10. Dybowski, C, Lowe, B, Brunahl, C. Predictors of pain, urinary symptoms and quality of life in patients with chronic pelvic pain syndrome (CPPS): a prospective 12-month follow-up study. J Psychosom Res 2018;112:99–106. https://doi.org/10.1016/j.jpsychores.2018.06.013.Search in Google Scholar PubMed

11. Tripp, DA, Nickel, JC, Shoskes, D, Koljuskov, A. A 2-year follow-up of quality of life, pain, and psychosocial factors in patients with chronic prostatitis/chronic pelvic pain syndrome and their spouses. World J Urol 2013;31:733–9. https://doi.org/10.1007/s00345-013-1067-6.Search in Google Scholar PubMed

12. Engeler, D, Baranowski, AP, Borovicka, AM, Dinis-Oliveriea, P, Elneil, S, Hughes, J, et al.. EAU guidelines on chronic pelvic pain. European Association of Urology; 2021. Arnhem: EAU Guidelines Office. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Chronic-Pelvic-Pain-2021-large-text.pdf.Search in Google Scholar

13. Rees, J, Abrahams, M, Doble, A, Cooper, A, Prostatitis Expert Reference Group. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int 2015;116:509–25. https://doi.org/10.1111/bju.13101.Search in Google Scholar PubMed PubMed Central

14. Williams, AC, Eccleston, C, Morley, S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;11:CD007407. https://doi.org/10.1002/14651858.CD007407.pub3.Search in Google Scholar PubMed PubMed Central

15. Veehof, MM, Oskam, MJ, Schreurs, KMG, Bohlmeijer, ET. Acceptance-based interventions for the treatment of chronic pain: a systematic review and meta-analysis. Pain 2011;152:533–42. https://doi.org/10.1016/j.pain.2010.11.002.Search in Google Scholar PubMed

16. Veehof, MM, Trompetter, HR, Bohlmeijer, ET, Schreurs, KMG. Acceptance-and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. Cognit Behav Ther 2016;45:5–31. https://doi.org/10.1080/16506073.2015.1098724.Search in Google Scholar PubMed

17. Tripp, DA, Nickel, JC, Katz, L. A feasibility trial of a cognitive-behavioural symptom management program for chronic pelvic pain for men with refractory chronic prostatitis/chronic pelvic pain syndrome. Can Urol Assoc J 2011;5:328–32. https://doi.org/10.5489/cuaj.10201.Search in Google Scholar PubMed PubMed Central

18. Wang, J, Liang, K, Sun, H, Li, L, Wang, H, Cao, J. Psychotherapy combined with drug therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Int J Urol 2018;25:710–5. https://doi.org/10.1111/iju.13706.Search in Google Scholar PubMed

19. Franco, JVA, Turk, T, Jung, JH, Xiao, YT, Iakhno, S, Tirapegui, FI, et al.. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int 2020;125:490–6. https://doi.org/10.1111/bju.14988.Search in Google Scholar PubMed

20. Klotz, SGR, Ketels, G, Lowe, B, Brunahl, CA. Myofascial findings and psychopathological factors in patients with chronic pelvic pain syndrome. Pain Med 2020;21:e34–44. https://doi.org/10.1093/pm/pny097.Search in Google Scholar PubMed

21. Franco, JVA, Turk, T, Jung, JH, Xiao, YT, Iakhno, S, Garrote, V, et al.. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a cochrane systematic review. BJU Int 2019;124:197–208. https://doi.org/10.1111/bju.14492.Search in Google Scholar PubMed

22. Page, MJ, Moher, D, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160. https://doi.org/10.1136/bmj.n160.Search in Google Scholar PubMed PubMed Central

23. Higgins, JPT, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, et al.. editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. London: The Cochrane Collaboration. Available from www.training.cochrane.org/handbook.Search in Google Scholar

24. OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 2 Oxford centre for evidence-based medicine. Oxford: The University of Oxford. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence [Accessed 19 Apr 2022].Search in Google Scholar

25. Howick, J, Chalmers, I, Glasziou, P, Greenhalgh, T, Heneghan, C, Liberati, A, et al.. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). Oxford Centre for Evidence-Based Medicine. Oxford: The University of Oxford. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence [Accessed 19 Apr 2022].Search in Google Scholar

26. Thomas, BH, Ciliska, D, Dobbins, M, Micucci, S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evidence-Based Nurs 2004;1:176–84. https://doi.org/10.1111/j.1524-475X.2004.04006.x.Search in Google Scholar PubMed

27. Armijo-Olivo, S, Stiles, CR, Hagen, NA, Biondo, PD, Cummings, GG. Assessment of study quality for systematic reviews: a comparison of the cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research. J Eval Clin Pract 2012;18:12–8. https://doi.org/10.1111/j.1365-2753.2010.01516.x.Search in Google Scholar PubMed

28. Popay, J, Roberts, H, Sowden, A, Petticrew, M, Arai, L, Rodgers, M, et al.. Guidance on the conduct of narrative synthesis in systematic reviews. London: A product from the ESRC methods programme Version; 2006. [Accessed 19 Apr 2022].Search in Google Scholar

29. Anderson, RU, Wise, D, Sawyer, T, Chan, CA. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol 2006;176:1534–8. discussion 8–9. https://doi.org/10.1016/j.juro.2006.06.010.Search in Google Scholar PubMed

30. Anderson, RU, Wise, D, Sawyer, T, Glowe, P, Orenberg, EK. 6-day intensive treatment protocol for refractory chronic prostatitis/chronic pelvic pain syndrome using myofascial release and paradoxical relaxation training. J Urol 2011;185:1294–9. https://doi.org/10.1016/j.juro.2010.11.076.Search in Google Scholar PubMed

31. Anderson, RU, Wise, D, Sawyer, T, Nathanson, BH, Smith, JN. Equal improvement in men and women in the treatment of urologic chronic pelvic pain syndrome using a multi-modal protocol with an internal myofascial trigger point wand. Appl Psychophysiol Biofeedback 2016;41:215–24. https://doi.org/10.1007/s10484-015-9325-6.Search in Google Scholar PubMed

32. Lu, S, Jiang, D. Effect of cognitive intervention on the chronic prostatitis following sexually transmitted diseases. Chin J Clin Psychol 2005;13:225–6.Search in Google Scholar

33. Zhuang, G, Chen, B, Wu, S, Li, H, Yang, H. Clinical effect of cognitive therapy combined with drugs for type ⅢA prostatitis. Nan Xing Xue Za Zhi 2015;29:41–4.Search in Google Scholar

34. Propert, KJ, Litwin, MS, Wang, Y, Alexander, RB, Calhoun, E, Nickel, JC, et al.. Responsiveness of the national institutes of health chronic prostatitis symptom index (NIH-CPSI). Qual Life Res 2006;15:299–305. https://doi.org/10.1007/s11136-005-1317-1.Search in Google Scholar PubMed

35. Zhang, J, Zhang, X, Cai, Z, Li, N, Li, H. The lifetime risk and prognosis of chronic prostatitis/chronic pelvic pain syndrome in the middle-aged Chinese males. Am J Men’s Health 2019;13: 1557988319865380. https://doi.org/10.1177/1557988319865380.Search in Google Scholar PubMed PubMed Central

36. Chung, S-D, Lin, H-C. Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. PLoS One 2013;8:e64630. https://doi.org/10.1371/journal.pone.0064630.Search in Google Scholar PubMed PubMed Central

37. Chung, SD, Huang, CC, Lin, HC. Chronic prostatitis and depressive disorder: a three year population-based study. J Affect Disord 2011;134:404–9. https://doi.org/10.1016/j.jad.2011.05.046.Search in Google Scholar PubMed

38. Lee, SW. Recent trend of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) management. Hanyang Med Rev 2017;37:40–6. https://doi.org/10.7599/hmr.2017.37.1.40.Search in Google Scholar

39. Krsmanovic, A, Tripp, DA, Nickel, JC, Shoskes, DA, Pontari, M, Litwin, MS, et al.. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J 2014;8:403–8. https://doi.org/10.5489/cuaj.2179.Search in Google Scholar PubMed PubMed Central

40. Scott, EL, Kroenke, K, Wu, J, Yu, Z. Beneficial effects of improvement in depression, pain catastrophizing, and anxiety on pain outcomes: a 12-month longitudinal analysis. J Pain 2016;17:215–22. https://doi.org/10.1016/j.jpain.2015.10.011.Search in Google Scholar PubMed

41. Smeets, RJ, Vlaeyen, JW, Kester, AD, Knottnerus, JA. Reduction of pain catastrophizing mediates the outcome of both physical and cognitive-behavioral treatment in chronic low back pain. J Pain 2006;7:261–71. https://doi.org/10.1016/j.jpain.2005.10.011.Search in Google Scholar PubMed

42. Piontek, K, Ketels, G, Klotz, SGR, Dybowski, C, Brunahl, C, Lowe, B. The longitudinal association of symptom-related and psychological factors with health-related quality of life in patients with chronic pelvic pain syndrome. J Psychosom Res 2022;153:110707. https://doi.org/10.1016/j.jpsychores.2021.110707.Search in Google Scholar PubMed

43. Piontek, K, Ketels, G, Albrecht, R, Schnurr, U, Dybowski, C, Brunahl, CA, et al.. Somatic and psychosocial determinants of symptom severity and quality of life in male and female patients with chronic pelvic pain syndrome. J Psychosom Res 2019;120:1–7. https://doi.org/10.1016/j.jpsychores.2019.02.010.Search in Google Scholar PubMed

44. Piontek, K, Apfelbacher, C, Ketels, G, Brunahl, C, Lowe, B. Depression partially mediates the association of adverse childhood experiences with pain intensity in patients with chronic pelvic pain syndrome: results from a cross-sectional patient survey. Pain Med 2021;22:1174–84. https://doi.org/10.1093/pm/pnaa325.Search in Google Scholar PubMed

45. Sullivan, MJ, Bishop, SR, Pivik, J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524–32. https://doi.org/10.1037/1040-3590.7.4.524.Search in Google Scholar

46. Lovibond, PF, Lovibond, SH. The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the beck depression and anxiety inventories. Behav Res Ther 1995;33:335–43. https://doi.org/10.1016/0005-7967(94)00075-u.Search in Google Scholar PubMed

47. Kroenke, K, Spitzer, RL, Williams, JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13. https://doi.org/10.1046/j.1525-1497.2001.016009606.x.Search in Google Scholar PubMed PubMed Central

48. Spitzer, RL, Kroenke, K, Williams, JB, Lowe, B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7. https://doi.org/10.1001/archinte.166.10.1092.Search in Google Scholar PubMed

49. Dworkin, RH, Turk, DC, Farrar, JT, Haythornthwaite, JA, Jensen, MP, Katz, NP, et al.. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19. https://doi.org/10.1016/j.pain.2004.09.012.Search in Google Scholar PubMed

50. Dworkin, RH, Turk, DC, Wyrwich, KW, Beaton, D, Cleeland, CS, Farrar, JT, et al.. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–21. https://doi.org/10.1016/j.jpain.2007.09.005.Search in Google Scholar PubMed


Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/sjpain-2022-0049).


Received: 2022-03-18
Accepted: 2022-06-30
Published Online: 2022-08-09
Published in Print: 2023-01-27

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 29.5.2024 from https://www.degruyter.com/document/doi/10.1515/sjpain-2022-0049/html
Scroll to top button